Skip to main content
Year archive

Mendus — 2021 filings

All 54 regulatory filings released by Mendus (IMMU) in 2021, sourced directly from the official regulator.

54 Filings
2021 Period
2021 filings (54)
Filing Released Lang
Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021
Regulatory Filings
2021-12-11 Swedish
Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021
Regulatory Filings
2021-12-11 English
Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study
Regulatory Filings
2021-12-03 Swedish
Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study
Regulatory Filings
2021-12-03 English
Immunicum och PCI Biotech tillkännager förlängning av sitt forskningssamarbete med att utforska nya behandlingar med cancervaccin
Regulatory Filings
2021-11-30 Swedish
Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments
Regulatory Filings
2021-11-30 English
Immunicum Announces Nomination Committee for the 2022 Annual General Meeting
Board/Management Information
2021-11-03 English
Immunicum tillkännager valberedning inför årsstämman 2022
AGM Information
2021-11-03 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q3 2021
2021-10-28 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q3 2021
2021-10-28 English
Immunicum utser Lotta Ferm till CFO
Board/Management Information
2021-10-26 Swedish
Immunicum Appoints Lotta Ferm as Chief Financial Officer
Board/Management Information
2021-10-26 English
Immunicum AB (publ) Announces Outcome of Subscription in Incentive Program LTI 2021/2024
Remuneration Information
2021-09-29 English
Immunicum meddelar utfall av teckning i incitamentsprogram LTI 2021/2024
AGM Information
2021-09-29 Swedish
Earnings Release 2021
Earnings Release Q2 2021
2021-08-26 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-08-26 English
Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study
Regulatory Filings
2021-07-26 English
Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien
Legal Proceedings Report
2021-07-26 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-07-12 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-07-01 English
Förändring av antal aktier och röster i Immunicum AB (publ)
Share Issue/Capital Change
2021-06-30 Swedish
Change in Number of Shares and Votes in Immunicum AB (publ)
Share Issue/Capital Change
2021-06-30 English
Director's Dealing 2021
Director's Dealing
2021-06-22 English
Immunicum offentliggör utfallet av riktad emission av aktier
Share Issue/Capital Change
2021-06-17 Swedish
Immunicum Announces Results of Directed Share Issue
Capital/Financing Update
2021-06-17 English
Immunicum Announces its Intention to Carry Out a Directed Share Issue
Share Issue/Capital Change
2021-06-17 English
Immunicum offentliggör avsikt att genomföra en riktad emission av aktier
Share Issue/Capital Change
2021-06-17 Swedish
Kommuniké från årsstämma i Immunicum AB (publ) den 4 maj 2021
AGM Information
2021-05-04 Swedish
Report from the Annual General Meeting of Immunicum AB (publ) on 4 May 2021
AGM Information
2021-05-04 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-04 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-04 English
Immunicum AB (publ) offentliggör årsredovisning för 2020
Report Publication Announcement
2021-04-12 Swedish
Immunicum AB (publ) Publishes the Annual Report for 2020
Report Publication Announcement
2021-04-12 English
KALLELSE TILL ÅRSSTÄMMA I IMMUNICUM AB (PUBL)
AGM Information
2021-03-31 Swedish
Notice of Annual General Meeting in Immunicum am (publ)
AGM Information
2021-03-31 English
Immunicum AB (publ) meddelar förändringar i ledningsgruppen efter sammanslagningen
Board/Management Information
2021-03-16 Swedish
Immunicum AB (publ) Announces Updated Executive Management Team After Business Combination
Board/Management Information
2021-03-16 English
Immunicum AB (publ) meddelar att Jeroen Rovers har utsetts till medicinsk chef
Board/Management Information
2021-03-01 Swedish
Immunicum AB (publ) Announces Appointment of Jeroen Rovers as Chief Medical Officer
Board/Management Information
2021-03-01 English
Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer
Regulatory Filings
2021-02-22 Swedish
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
Regulatory Filings
2021-02-22 English
Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från EMA för ilixadencel för behandling av gastrointestinal stromacellstumör (GIST)
Legal Proceedings Report
2021-02-19 Swedish
Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST)
Regulatory Filings
2021-02-19 English
Interim / Quarterly Report 2020
Interim / Quarterly Report FY 2020
2021-02-18 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q4 2020
2021-02-18 English
Immunicum AB (publ) meddelar att Lotta Ferm har utsetts till ny tillförordnad finanschef
Board/Management Information
2021-02-01 Swedish
Immunicum AB (publ) Announces New Interim CFO Lotta Ferm
Board/Management Information
2021-02-01 English
Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS)
Regulatory Filings
2021-01-26 English
Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av mjukdelssarkom, Soft Tissue Sarcoma (STS)
Regulatory Filings
2021-01-26 Swedish
Kommuniké från extra bolagsstämma i Immunicum AB (publ) den 22 januari 2021
AGM Information
2021-01-22 Swedish
Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021
AGM Information
2021-01-22 English
Immunicum AB (publ) Announces Transitions in Board of Directors
Board/Management Information
2021-01-21 English
Immunicum AB (publ) meddelar förändringar i styrelsen
Board/Management Information
2021-01-21 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-01-04 Swedish